1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

CMS Innovation Center Exploring ‘Array’ Of Cost-Lowering Medicare Payment Models

 
• By Cathy Kelly

CMMI payment demonstrations are viewed as way of skirting statutory obstacles to experimenting with new approaches to reimbursement and could lead to significant drug pricing reforms if legislative efforts fail. However, HHS is not signaling an intent to pursue transformational new models at this point.

Drug costs_1B_546120055_1200.jpg
• Source: Shutterstock

The Center for Medicare and Medicaid Innovation is considering a variety of different payment models that could be tested as a way to lower costs in Medicare Parts B and D, the Health and Human Services Department notes in its Comprehensive Plan for Addressing High Drug Prices, released on 9 September.

The report includes a wide range of administrative policies under consideration or already underway at federal agencies and also endorses...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

Belgium Competition Authority Tackles Reimbursement Barriers For Combination Drugs

 
• By Francesca Bruce

The Belgian Competition Authority has set out guidance on how pharmaceutical companies can share information on combination therapies when seeking their reimbursement.

Clawbacks And Clinical Trial Set Up Are Among UK’s Investment Deterrents

 
• By Francesca Bruce

In the wake of MSD’s decision not to invest $1.35bn in the UK, the Association of the British Pharmaceutical Industry has set out the county’s comparative strengths and weaknesses.

Medicare Price Negotiation Should Not Exclude Acquisitions From R&D Spending, CMS Told

 
• By Cathy Kelly

Excluding information about acquisition costs could indicate a manufacturer had no R&D spending to recoup for a drug selected for Medicare price negotiation, which could cause CMS to inappropriately lower its price offer.

340B Rebate Model Pilot: Dispute Over Providers’ Administrative Burden, Costs

 
• By Cathy Kelly

Hospitals urged HRSA to require that manufacturers cover all costs associated with their participation, while pharma argued for a more narrowly defined responsibility, as model implementation moves forward.

More from Market Access

Japan Expands Essential Drug List For Economic Security

 
• By Lisa Takagi

Japan's government has already allocated more than $400m to repatriate manufacturing of important drugs and continues to provide support as it expands a list of "national security" drugs.

Do Policy, Clinical Data, Ocaliva Exit Lend Zydus Helping Hands?

 
• By Vibha Ravi

Intercept’s Ocaliva withdrawal in the US places the spotlight on emerging PBC candidates like Zydus’s saroglitazar, a PPAR agonist that beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results. Will the withdrawal and policy developments boost Zydus’s prospects?

More Vaccines At Risk At Upcoming ACIP Meeting As New Panel Members Join

 
• By Sarah Karlin-Smith

The ACIP put hepatitis B and MMRV vaccines on its agenda, despite having no new reason to relitigate the products, worrying public health experts that more anti-vaccine moves are coming.